HCV+PWID

PreclinicalSmall molecule

YYale University

HCV+PWID is one of 26 small molecule programs targeting Drug. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DrugCompleted

DrugPreclinical

Completed

Competition

Competitive Landscape

29 competitors in Drug

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

1 2

Inderal

WWyeth-Lederle Vaccines

Approved

1 3

Ketalar

AAultman Health Foundation

Phase 3

1 4

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 5

Keytruda

Merck & Co.

Phase 2

1 6

Lenvima

Eisai

Phase 2

1 7

Pepcid

KKenvue Brands

Phase 1

7 8

BAY 987519

Bayer

Phase 1

1 9

Sovaldi

Gilead

Preclinical

2 10

Prostigmin

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug1 trial

Testing and Linkage to Care for Injecting Drug Users in Kenya

Completed·YYale University·N/A·NCT01557998·9,449 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HCV+PWID. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HCV+PWID compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HCV+PWID. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYale University